Guisado-Vasco: Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort) [HCQ]

Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)

Guisado-Vasco

Guisado-Vasco, Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary..,

Oct 2020 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 607 patients reporting results for early outpatient HCQ use with mortality odds ratio OR 0.092 [0.022-0.381], p = 0.001 (65 patients), and for hospital use, mortality odds ratio OR 0.737 [0.38-1.41], p = 0.36 (558 patients). Median age 69.

Important missing comments or errors? Let us know.

risk of death, 20.3% lower, RR 0.80, p = 0.36, treatment 127 of 558 (22.8%), control 14 of 49 (28.6%), NNT 17, adjusted per study, odds ratio converted to relative risk.

outpatient use, 88.0% lower, RR 0.12, p = 0.001, treatment 2 of 65 (3.1%), control 139 of 542 (25.6%), NNT 4.4, adjusted per study, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Guisado-Vasco et al., 15 Oct 2020, retrospective, Spain, peer-reviewed, median age 69.0, 25 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Abstract: EClinicalMedicine 28 (2020) 100591 Contents lists available at ScienceDirect EClinicalMedicine journal homepage: https://www.journals.elsevier.com/eclinicalmedicine Research Paper Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort) n-Gonza leza, Pablo Guisado-Vascoa,*, Soﬁa Valderas-Ortegab, Maria Maravillas Carralo c d a lez-Cortijo , Gabriel Sotres-Ferna ndez , Ana Roda-Santacruz , Lucia Gonza e a Eva María Martí-Ballesteros , Jose Manuel Luque-Pinilla , Elena Almagro-Casadod, lix J. La Coma-Lanuzaf, Ruth Barrena-Puertasa, Esteban Javier Malo-Benagesg, Fe Monforte-Go mezh, Rocío Diez-Munari, Esther Merino-Lanzaj, María Jose Lorena Comeche-Casanovak, Margarita Remirez-de-Esparza-Oterol, María Correyero-Plazam, pezo, María Dolores Sa nchez-Manzanoa, Manuel Recio-Rodríguezn, Margarita Rodríguez-Lo zquezp, Israel John Thuissard-Vasallop, Cristina Andreu-Va María Echave-Sustaeta María-Tome k, Daniel Carnevali-Ruiza Jose a Department of Internal Medicine. Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain Nurse. Hospital Infectious Diseases Control Unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain Research coordinator. Research and clinical trials unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain d Department of Oncology. Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain e Department of Hematology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain f Intensive Care Unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain g Department of Angiology and Vascular Surgery, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain h Department of Internal Medicine, Hospital quironsalud San Jose, Madrid, Spain i Department of Anesthesiology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain j Department of Cardiology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain k Department of Pneumology, Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain l Pharmacy Unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain m Department of Rheumatology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain n Department of Radiology department, Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain o Department of Endocrinology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain p n, Madrid, Spain Statistical section, Faculty of Biomedical Science and Health, Universidad Europea (Madrid), Villaciosa de Odo b c A R T I C L E I N F O Article History: Received 8 July 2020 Revised 22 September 2020 Accepted 25 September 2020 Available online 15 October 2020 Keywords: Severe COVID-19 SARS-CoV-2 infection Cyclosporine a Acute respiratory insufﬁciency Immunosuppressants Hyperinﬂammation state A B S T R A C T Background: The COVID-19 outbreak challenges the Spanish health system since March 2020. Some available therapies..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit